{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:39:12Z","timestamp":1784623152100,"version":"3.55.0"},"reference-count":15,"publisher":"Scientific Scholar","content-domain":{"domain":["ruralneuropractice.com"],"crossmark-restriction":true},"short-container-title":["JNRP"],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Objectives:<\/jats:title>\n<jats:p>Levetiracetam (LEV) is a well-established broad spectrum antiseizure medication (ASM) effective in focal, generalized, and myoclonic seizures whereas lacosamide (LCM) is a comparatively newer ASM currently approved only as an add-on agent in focal seizures. The aim of the study was to assess the efficacy and the tolerability of oral LCM as monotherapy in adult people with epilepsy (PWE) with new onset focal onset epilepsy compared with those receiving LEV.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>In this open-label single-center non-inferiority trial, PWE aged between 16 and 65 years suffering from new onset focal seizures, with or without secondary generalization were put on LCM monotherapy or LEV monotherapy. Data regarding demographic characteristics, seizure type and etiology, LCM and LEV daily dose, seizure frequency at baseline and at 6 months of follow-up, and seizure freedom rates were recorded.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Results:<\/jats:title>\n<jats:p>Thirty-five PWE on LCM (24 males), their mean age: 38.20 \u00b1 16.62 years and 35 PWE on LEV (25 males, mean age: 38.91 \u00b1 17.13 years) were enrolled. The most common type of seizure observed was focal to bilateral tonic-clonic seizure &gt;70% followed by focal impaired awareness seizure and focal awareness seizure. Structural epilepsy was found in 21 among LCM group and 22 of LEV group. In the LCM group, the seizure frequency decreased from 3.33 \u00b1 1.88 to 0.85 \u00b1 1.09 (<jats:italic>P<\/jats:italic> = 0.001) at 6 months and from 3.61 \u00b1 3.12 to 0.94 \u00b1 1.24 (<jats:italic>P<\/jats:italic> = 0.001) in LEV group, intergroup difference (<jats:italic>P<\/jats:italic> = 0.74). At 6-month follow-up period, 78.9% in LCM arm and 87.9% in the LEV arm had experienced a 50% of reduction in seizure frequency while seizure freedom was attained in 43.3% of PWE in both the arms (<jats:italic>P<\/jats:italic> = 1). The most common treatment emergent adverse effects in the LCM group were fatiguability, dyspepsia, headache, and dizziness, while in the LEV group; somnolence and behavioral abnormality.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Treatment with LCM met the non-inferiority criteria when compared with LEV. Therefore, it might be useful as first-line monotherapy for adults with newly diagnosed focal epilepsy.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/jnrp_182_2023","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T06:20:09Z","timestamp":1688019609000},"page":"622-628","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Equipotency of lacosamide to levetiracetam in new onset focal epilepsy: A randomized controlled trial"],"prefix":"10.25259","volume":"14","author":[{"given":"Binaya Kumar","family":"Jaiswal","sequence":"first","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev Kumar","family":"Bhoi","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menka","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Samal","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Porey","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"10.25259\/JNRP_182_2023\/ref-1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.yebeh.2019.02.022","article-title":"Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study","volume":"94","author":"Del Bianco","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.25259\/JNRP_182_2023\/ref-4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: Comparison of efficacy and safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"key":"10.25259\/JNRP_182_2023\/ref-6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: Results from a Phase III open-label extension trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.25259\/JNRP_182_2023\/ref-9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: A phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.25259\/JNRP_182_2023\/ref-10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: A prospective, open-label, observational, multicenter study in Spain","volume":"12","author":"Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R D"},{"key":"10.25259\/JNRP_182_2023\/ref-11","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1111\/epi.13502","article-title":"Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial","volume":"57","author":"Vossler","year":"2016","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/epi.13671","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-13","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1111\/epi.16381","article-title":"Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy","volume":"60","author":"Ben-Menachem","year":"2019","journal-title":"Epilepsia"},{"key":"10.25259\/JNRP_182_2023\/ref-14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40262-015-0276-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of lacosamide","volume":"54","author":"Cawello","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.25259\/JNRP_182_2023\/ref-15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"}],"container-title":["Journal of Neurosciences in Rural Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ruralneuropractice.com\/equipotency-of-lacosamide-to-levetiracetam-in-new-onset-focal-epilepsy-a-randomized-controlled-trial\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ruralneuropractice.com\/equipotency-of-lacosamide-to-levetiracetam-in-new-onset-focal-epilepsy-a-randomized-controlled-trial\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T09:07:46Z","timestamp":1699693666000},"score":1,"resource":{"primary":{"URL":"https:\/\/ruralneuropractice.com\/equipotency-of-lacosamide-to-levetiracetam-in-new-onset-focal-epilepsy-a-randomized-controlled-trial\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":15,"alternative-id":["10.25259\/JNRP_182_2023"],"URL":"https:\/\/doi.org\/10.25259\/jnrp_182_2023","relation":{},"ISSN":["0976-3155","0976-3147"],"issn-type":[{"value":"0976-3155","type":"electronic"},{"value":"0976-3147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"article-number":"622"}}